• Molecular NameHexylcaine
  • SynonymNA
  • Weight261.365
  • Drugbank_IDDB00473
  • ACS_NO532-77-4
  • Show 2D model
  • LogP (experiment)3.878
  • LogP (predicted, AB/LogP v2.0)3.11
  • pka9.1
  • LogD (pH=7, predicted)0.71
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.3
  • LogSw (predicted, AB/LogsW2.0)0.39
  • Sw (mg/ml) (predicted, ACD/Labs)0.15
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds6
  • TPSA38.33
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA short-acting local anesthetic. It acts by inhibiting sodium channel conduction.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolyzed by plasma esterases to benzoic acid and other derivatives
  • Half life<10 min
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of anesthetic overdose include headache, tinnitus, circumoral and tongue paresthesias, restlessness, talkativeness, facial twitching, convulsions, respiratory arrest, and cardiac depression
  • LD50 (rat)N/A
  • LD50 (mouse)N/A